Tecan uses cookies to improve our website. By continuing to browse our website, you accept our cookie policy.

This content is available also in other languages


This content is available also in other languages

October 25, 2005 | Customer News

Tecan and Promega co-develop large volume genomic DNA purification system

  Tecan has released the Freedom EVO®|gDNA XL for the automated purification of genomic DNA (gDNA) ready for use in downstream applications including genotyping, genome analysis and real-time PCR. Eluted gDNA can be prepared from fresh, refrigerated or frozen whole blood samples by incorporating the recently launched chemistry of the Promega MagneSil® Genomic Large Volume System with the flexible Freedom EVO workstation technology.

The Freedom EVO|gDNA XL is a powerful, fully automated system that purifies gDNA from samples from primary tubes, for example Vacutainer® tubes, without needing user intervention for further treatments such as pellet resuspension. The purification method automatically detects sample volume levels and scales all reagent volumes accordingly without additional programming. The system provides long walk-away times by eliminating the need for laborious centrifugation steps and the use of organic solvents. Its robust hardware, software and protocol are all scalable, allowing sample sizes of 1-10 ml in a single run and 1-96 samples per batch, minimizing reagent wastage.

The Freedom EVO|gDNA XL is the first in a line of systems that couples Promega's DNA purification applications with Tecan's expertise in automation to deliver fast, reliable and easy to use systems that generate proven results.

About Tecan

Tecan (www.tecan.com) is a leading player in the Life Sciences supply industry that specializes in the development, production, and distribution of solutions enabling the discovery of pharmaceutical substances, as well as for genomics, proteomics, and diagnostics. Through its subsidiary REMP (www.remp.com) Tecan is a leading supplier of compound and sample storage, managerial and logistic solutions. Tecan clients are leading pharmaceutical and biotechnology companies, university research departments and diagnostic laboratories. Founded in Switzerland in 1980, the company has manufacturing, research and development sites in both North America and Europe and maintains a sales and service network in 52 countries. In 2004, Tecan achieved sales of CH 286.0 million (USD 230.6 million; EUR 185.7 million). Registered shares of Tecan Group are traded on the SWX Swiss Exchange (TK: TECN / Reuters: TECZn.S / Valor: 1210019).

For further information please contact:

Tecan Switzerland AG
Seestrasse 103
CH-8708 Männedorf

T +41 44 922 81 11
F +41 44 922 81 12